News and Trends 20 Apr 2023 FDA approves Genentech’s lymphoma drug Genentech, a member of the Roche Group, has announced the U.S. Food and Drug Administration (FDA) has approved Polivy (polatuzumab vedotin-piiq) in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP). The approval covers the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell […] April 20, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Sponsored by Business France 20 Apr 2023 8 life science innovators you must meet at BioTrinity 2023 April 20, 2023 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 19 Apr 2023 How Vaccine Platforms Can Prepare Us for Future Pandemics The COVID-19 pandemic exposed the weaknesses in our defenses. Vaccine platforms will be powerful tools for reacting faster to future pandemics. Multiple COVID-19 vaccines became available across the world to tackle the COVID-19 pandemic, signaling a historic moment for vaccine development due to the speed at which they were created. And with scientists believing that […] April 19, 2023 - 7 minutesmins - By Sachin Rawat Share WhatsApp Twitter Linkedin Email
In Depth 14 Apr 2023 mRNA vaccines: a promising future In 1978, nearly two decades after the discovery of messenger RNA (mRNA), the concept of a vaccine made from mRNA was materialized. Like its name suggests, mRNAs are messengers that aid in decoding genetic information from DNA to synthesize proteins, a key cellular function. Previous attempts at developing a vaccine using mRNA failed because mRNA […] April 14, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 14 Apr 2023 TORL BioTherapeutics launches with $158M to target cancer TORL BioTherapeutics LLC, a biopharmaceutical company focused on developing new biologics for cancer treatment, has announced its public launch and the closing of a $158 million Series B financing. TORL’s pipeline of antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) were discovered in the laboratory of scientific co-founder Dennis Slamon, professor of medicine, and chief of […] April 14, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Apr 2023 Researchers explain how some lung tumors avoid immunotherapy The oncogenic activation of MYC, a critical gene in cancer progression, has the potential to identify lung cancer patients who may respond poorly to immunotherapy. This is the main conclusion of a study recently published by a team of researchers led by Montse Sanchez-Cespedes, principal investigator of the Cancer Genetics group at the Josep Carreras […] April 14, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Apr 2023 biomodal launches new multiomics sequencing technology biomodal, formerly known as Cambridge Epigenetix, has launched its new duet multiomics solution, which it says reveals the combinatorial power of genetic and epigenetic information from a single low volume sample. The duet multiomics solution is the world’s first single-base-resolution sequencing technology that enables the simultaneous phased reading of genetic and epigenetic information in a […] April 14, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Podcast 14 Apr 2023Beyond Biotech podcast 41: Sarcoidosis This week, to coincide with World Sarcoidosis Day, we talk about sarcoidosis with Marcin Szumowski, CEO and president of the management board of Molecure. World Sarcoidosis Day As part of Sarcoidosis Awareness Month, which is observed each April, World Sarcoidosis Day is held on April 13. But what is sarcoidosis? The Foundation for Sarcoidosis Research […] April 14, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2023 Alentis Therapeutics raises $105M for claudin platform Alentis Therapeutics is a clinical-stage biotech developing treatments for organ fibrosis and claudin-1 (CLDN1) positive tumors. The company has announced $105 million in Series C financing. The funding round was led by Jeito Capital, Novo Holdings A/S and RA Capital Management with participation from existing investors including BB Pureos Bioventures, Bpifrance through its InnoBio 2 […] April 13, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2023 Sumitomo Pharma Oncology receives orphan drug designation for Ewing sarcoma treatment Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, said the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for TP-1287, an investigational oral CDK9 inhibitor, for the treatment of Ewing sarcoma. “We are delighted to have received this designation for TP-1287 which underscores the need for additional treatment […] April 11, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2023 Intracellular drug delivery startup Vitarka Therapeutics raises £1.27M Vitarka Therapeutics, which focuses on non-viral drug delivery technology, has raised £1.27 million ($1.58 million) in equity from venture capital firm SOSV, the UK Innovation & Science Seed Fund (UK12S) and grant funding from Innovate UK. Founded in 2021 by Vineeta Tripathi, Vitarka Therapeutics is developing combination medicines using RNAi therapies and a non-viral drug […] April 11, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Apr 2023 Mosaic Therapeutics closes $28M series A funding Mosaic Therapeutics, Ltd has closed its $28 million series A funding round. The investment in this round was raised from Syncona Investment Management, Ltd, and Cambridge Innovation Capital. The company also announced the appointment of former Novartis Oncology SVP Brian Gladsden as CEO. The Series A funding will be used to further advance Mosaic Therapeutics’ pipeline […] April 5, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email